2H-1,4-benzothiazine-3(4H)-thione | 22191-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 2H-1,4-benzothiazine-3(4H)-thione
• 英文别名: 4H-1,4-benzothiazine-3-thione
• CAS: 22191-30-6
• 化学式: C₈H₇NS₂
• mdl: MFCD02082224
• 分子量: 181.282
• InChiKey: AQWCHSYEHJCCNU-UHFFFAOYSA-N

物化性质

• 溶解度：
  25.1 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2H-1,4-benzothiazine-3(4H)-thione 在 过氧乙酸 、 sodium hydride 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.42h， 生成 2,3-dihydro-3-oxo-5H-pyrido<3,4-b><1,4>benzothiazine-4-carbonitrile 10-oxide
  参考文献：
  名称：

  2,3-二氢-3-氧代-5H-吡啶并[3,4-b] [1,4]苯并噻嗪-4-腈的合成，苯并二氮杂receptor受体结合及抗惊厥活性。

  摘要：

  制备了一系列的氧代吡咯并苯并噻嗪（氮杂吩噻嗪），并评估了其与苯并二氮杂in受体的结合，戊戊四唑诱发的抽搐试验中的抗惊厥活性，以及​​在两种情况下，通过标准冲突试验提高了惩罚能力。尽管母体化合物1a的结合亲和力可与氯二氮杂卓（CDP）媲美，但其在抗惊厥试验和抗冲突试验中的功效比CDP弱得多。在合成的各种衍生物中，只有7-氯化合物1b的受体亲和力与1a相当，体内活性略有改善。受体结合与体内活性之间的不良相关性可能归因于与苯二氮卓受体亲和力无关的吸收或药理反应差异。

  DOI：

  10.1021/jm00360a011
• 作为产物：
  描述：

  Triphenyl-[2-(trimethylsilylmethylsulfanyl)phenyl]imino-lambda5-phosphane 在 氯化铵 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 52.0h， 生成 2H-1,4-benzothiazine-3(4H)-thione
  参考文献：
  名称：

  Synthesis of 2-Substituted 2,3-Dihydro-1,4-benzothiazine-3-thiones via Iminophosphoranes

  摘要：

  2-(Substituted methylsulfanyl)anilines (5) were treated with triphenylphosphine dibromide to yield iminophosphoranes (6), whose aza-Wittig reaction with carbon disulfide gave 2-(substituted methylsulfanyl)phenyl isothiocyanates(8). Cyclization of 8 by strong bases afforded 2-substituted 2,3-dihydro-1,4-benzothiazine-3-thiones (10).

  DOI：

  10.3987/com-95-7171

文献信息

• [EN] SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF<br/>[FR] 2-BENZYLIDÈNE-2H-BENZO[B][1,4]THIAZIN-3(4H)-ONES SUBSTITUÉES, DÉRIVÉS DE CELLES-CI, ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：UNIV TEMPLE

  公开号：WO2012166586A1

  公开（公告）日：2012-12-06

  The present invention relates to compounds according to Formula I and salts thereof, wherein R1, R2, R3, R4, Ar, and n are as defined herein. Methods for preparing compounds of Formula I are also provided. The present invention further includes methods of treating cellular proliferative disorders, such as cancer, with the compounds of Formula I.

  本发明涉及根据公式I的化合物及其盐，其中R1、R2、R3、R4、Ar和n如本文所述定义。还提供了制备公式I化合物的方法。本发明进一步包括使用公式I的化合物治疗细胞增殖障碍的方法，例如癌症。
• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090233920A1

  公开（公告）日：2009-09-17

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.

  该发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=紊乱）；该类化合物用于制备用于治疗依赖肾素活性疾病的药物配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的药物配方，和/或包括给予3,5-取代哌啶化合物的治疗方法，一种用于制造3,5-取代哌啶化合物的方法，以及其合成的新中间体和部分步骤。优选的化合物（也可以存在为盐）具有式I的结构，其中R1、R2、T、R3和R4如规范中定义。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2011151361A1

  公开（公告）日：2011-12-08

  The invention relates to tricyclic derivatives, and their use in treating diseases and conditions mediated by antagonism of the mGluR5 receptor, in particular substance related disorders. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

  该发明涉及三环衍生物，以及它们在治疗通过mGluR5受体拮抗作用介导的疾病和状况中的应用，尤其是与物质相关的障碍。此外，该发明还涉及包含这些衍生物的组合物及其制备过程。
• 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
  申请人：Horiuchi Yoshihiro

  公开号：US20120225876A1

  公开（公告）日：2012-09-06

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)

  公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中，A代表由公式(A-1)表示的基团；R1a和R1b可以相同或不同，每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基；m和n各自独立地表示0-5之间的整数；X1代表羟基或氨基甲酰基；Z1代表单键等；R2代表一个可选地取代的C1-6烷基，一个可选地取代的C6-10芳基等)。
• Benzothiazinone and benzoxazinone compounds
  申请人：Abbott GmbH & Co. KG

  公开号：US07049312B1

  公开（公告）日：2006-05-23

  Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2— R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R2 is H or a substituent R3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic group n is an integer from 0 to 1 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

  Q是-N=或CR2 X是S，O或NOR3 Y是-O-，-S-，-SO-或-SO2-R和R1分别是H，一个取代或未取代的脂肪族，芳香族，杂环芳香族或芳基烃基团R2是H或一个取代基R3是H，或-C(O)R4 R4是一个取代或未取代的脂肪族或芳香族团n是从0到1的整数具有结构式I和其生理上可接受的盐的化合物，是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种酪氨酸激酶参与血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞过度增殖是因素的疾病状态。这些化合物可用于治疗癌症和过度增殖性疾病。